190 related articles for article (PubMed ID: 33864956)
1. High levels of Tim-3
Zhong W; Liu X; Zhu Z; Li Q; Li K
Int Immunopharmacol; 2021 Jul; 96():107662. PubMed ID: 33864956
[TBL] [Abstract][Full Text] [Related]
2. The prevalence and function of CD4
Cha Z; Gu H; Zang Y; Wang Z; Li J; Huang W; Qin A; Zhu L; Tu X; Cheng N; Song H; Qian B
Int Immunopharmacol; 2018 Aug; 61():132-139. PubMed ID: 29870918
[TBL] [Abstract][Full Text] [Related]
3. Granzyme B-expressing treg cells are enriched in colorectal cancer and present the potential to eliminate autologous T conventional cells.
Sun B; Liu M; Cui M; Li T
Immunol Lett; 2020 Jan; 217():7-14. PubMed ID: 31669380
[TBL] [Abstract][Full Text] [Related]
4. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3
Zhang T; Ren T; Song Z; Zhao J; Jiao L; Zhang Z; He J; Liu X; Qiu L; Li L; Zhou S; Meng B; Zhai Q; Ren X; Qian Z; Wang X; Zhang H
J Immunol Res; 2020; 2020():6968595. PubMed ID: 33178839
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX
Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635
[TBL] [Abstract][Full Text] [Related]
6. Overrepresentation of highly functional T regulatory cells in patients with nonfunctioning pituitary adenoma.
Han S; Ma E; Jiang W; Lu Y; Sun X; Feng S
Hum Immunol; 2020 Jun; 81(6):314-319. PubMed ID: 32279926
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral FOXP3+ Regulatory T Cells in Diffuse Large B-Cell Lymphoma.
Serag El-Dien MM; Abdou AG; Asaad NY; Abd El-Wahed MM; Kora MAEM
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):534-542. PubMed ID: 26862953
[TBL] [Abstract][Full Text] [Related]
8. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment.
Banerjee H; Nieves-Rosado H; Kulkarni A; Murter B; McGrath KV; Chandran UR; Chang A; Szymczak-Workman AL; Vujanovic L; Delgoffe GM; Ferris RL; Kane LP
Cell Rep; 2021 Sep; 36(11):109699. PubMed ID: 34525351
[TBL] [Abstract][Full Text] [Related]
9. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.
Keane C; Tobin J; Gunawardana J; Francis S; Gifford G; Gabrielli S; Gill A; Stevenson W; Talaulikar D; Gould C; Jain S; Birch S; Hertzberg M; Gandhi MK
Eur J Haematol; 2019 Sep; 103(3):200-207. PubMed ID: 31211907
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis.
Lee NR; Song EK; Jang KY; Choi HN; Moon WS; Kwon K; Lee JH; Yim CY; Kwak JY
Leuk Lymphoma; 2008 Feb; 49(2):247-56. PubMed ID: 18231910
[TBL] [Abstract][Full Text] [Related]
11. Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma.
Xiao T; Zhang L; Chen L; Liu G; Feng Z; Gao L
Tumour Biol; 2014 Aug; 35(8):7951-6. PubMed ID: 24833097
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
[TBL] [Abstract][Full Text] [Related]
13. Significance of TIM-3 expression by CD4
Shariati S; Ghods A; Zohouri M; Rasolmali R; Talei AR; Mehdipour F; Ghaderi A
Mol Immunol; 2020 Dec; 128():47-54. PubMed ID: 33068833
[TBL] [Abstract][Full Text] [Related]
14. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells.
Gautron AS; Dominguez-Villar M; de Marcken M; Hafler DA
Eur J Immunol; 2014 Sep; 44(9):2703-2711. PubMed ID: 24838857
[TBL] [Abstract][Full Text] [Related]
15. Defective Treg response in acute kidney injury was caused by a reduction in TIM-3
Dong Q; Cai C; Gao F; Chen P; Gong W; Shen M
Immunol Invest; 2019 Jan; 48(1):27-38. PubMed ID: 29985717
[TBL] [Abstract][Full Text] [Related]
16. Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma.
Głowala-Kosińska M; Chwieduk A; Nieckula J; Saduś-Wojciechowska M; Grosicki S; Rusin A; Nowara E; Giebel S
Eur J Haematol; 2013 Aug; 91(2):122-8. PubMed ID: 23679234
[TBL] [Abstract][Full Text] [Related]
17. Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma.
Huang L; Xu Y; Fang J; Liu W; Chen J; Liu Z; Xu Q
Front Immunol; 2021; 12():654749. PubMed ID: 33936081
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of FOXP3
Bai Y; He T; Zhang L; Liu Q; Yang J; Zhao Z; Yang K; Zhang M
BMJ Open; 2022 Sep; 12(9):e060659. PubMed ID: 36691128
[TBL] [Abstract][Full Text] [Related]
19. T follicular helper cell-mediated IL-21 production suppresses FOXP3 expression of T follicular regulatory-like cells in diffuse large B cell lymphoma patients.
Ma X; Zha J; He J; Chen L; Huang J; Wu W; Tian P; Qian BH; Yu L; Jiang Y; Xu B
Hum Immunol; 2020 Aug; 81(8):452-459. PubMed ID: 32534760
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
